Radiation Oncology
A Cross-Sectional View of Radiation Dose Fractionation Schemes Used for Treating Painful Bone Metastases (PBM) Within Veterans Health Administration’s Radiation Oncology Centers.
Author(s): George Anthony Dawson, et al.
Background: The use of single fraction radiotherapy in the treatment of PBM in the United States is now gaining clinical acceptance, especially at large institutional levels. In this cross-sectional report, the authors report the varying dose fractionation schemes used to treat PBM by VHA radiation oncology centers.
To read the full abstract click here: http://meetinglibrary.asco.org/content/161496-176
Will Academic and Community Physicians Engage and Share Knowledge in an Online Physician Social Network? Lessons from the Radiation Oncology Community.
Author(s): Nadine Housri, et al.
Background: The exponential growth of medical knowledge has made it increasingly difficult for clinicians to make sense of new information and recognize how to incorporate new research results into clinical practice. The authors sought to determine whether a social question and answer website designed to connect academic and community physicians would consistently engage radiation oncologists to share evidence based information and clinical insights with each other.
To read the full abstract click here: http://meetinglibrary.asco.org/content/171497-176
Lung Cancer
Non–Small Cell Lung Cancer in Veterans: Disparities in Prevalence and Survival Among Different Histologic Subtypes.
Author(s): Hussein Assi, Efstratios Koutroumpakis, et al.
Background: Since the 1980s, adenocarcinoma (AC) of the lung has become more common than squamous cell carcinoma (SCC). Given the differences in smoking patterns, it is unclear if the same holds true among veterans. In this study, the authors compare the distribution of lung AC and SCC in the veterans’ population to that in the general population. They also looked at the survival of patients with different histologies in the VA population.
To read the full abstract click here: http://meetinglibrary.asco.org/content/167505-176
VA Oncologists’ Attitudes and Behaviors Regarding Genomic-Based Targeted Therapy for the Management of Advanced Lung Cancer.
Author(s): Jennifer Arney, et al.
Background: Genomic-based targeted therapy (GBTT) has emerged as a treatment option for patients with advanced lung cancer. Clinical practice guidelines of the National Comprehensive Cancer Network and the American Society of Clinical Oncology recommend testing all metastatic adenocarcinomas for EGFR mutation, and use of EGFR-TKIs (erlotinib) as first-line therapy for advanced adenocarcinoma lung cancer patients with EGFR mutation positive. Little is known about how oncologists utilize genomic testing and GBTT in a clinical setting. Drawing from the Cabana and colleagues theoretical framework on providers’ adherence to guidelines, this study aims to elicit provider and facility-level barriers and facilitators to using GBTT in VA healthcare delivery system.
To read the full abstract click here: http://meetinglibrary.asco.org/content/166517-176
[Click through for: Colorectal, HIV and Cancer, Palliative Care, Esophageal]
